TY - JOUR T1 - Evaluating the neuroprotective impact of senolytic drugs on human vision JF - medRxiv DO - 10.1101/2020.07.27.20163097 SP - 2020.07.27.20163097 AU - Nevin W. El-Nimri AU - Spencer M. Moore AU - Linda M. Zangwill AU - James A. Proudfoot AU - Robert N. Weinreb AU - Dorota Skowronska-Krawczyk AU - Sally L. Baxter Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/07/29/2020.07.27.20163097.abstract N2 - Glaucoma, a chronic neurodegenerative disease of retinal ganglion cells (RGCs), is a leading cause of irreversible blindness worldwide. Its management currently focuses on lowering intraocular pressure to slow disease progression. However, disease-modifying, neuroprotective treatments for glaucoma remain a major unmet need. Recently, senescent cells have been observed in glaucomatous eyes, exposing a potential pathway for alternative glaucoma therapies. Prior studies demonstrated that targeting senescent RGCs for removal (i.e., a senolytic approach) protected healthy RGCs and preserved visual function in a mouse ocular hypertension model. However, the effects of senolytic drugs on vision in human patients are unknown. Here, we used existing clinical data to conduct a retrospective cohort study in 28 human glaucoma patients who had been exposed to senolytics. Senolytic exposure was not associated with decreased visual acuity, elevated intraocular pressure, or documentation of senolytic-related adverse ocular effects by treating ophthalmologists. Additionally, patients exposed to senolytics (n=9) did not exhibit faster progression of glaucomatous visual field damage compared to matched glaucoma patients (n=26) without senolytic exposure. These results suggest that senolytic drugs do not carry significant ocular toxicity and provide further support for additional evaluation of the potential neuroprotective effects of senolytics on glaucoma and other neurodegenerative diseases.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was supported by grants from the National Institutes of Health (T15LM011271, P30EY022589, EY027011, EY11008, EY19869, EY14267, EY027510, EY026574, EY027945, EY029058) and by RPB Unrestricted Grant to Shiley Eye Institute. Work in the DSK laboratory was additionally supported by RPB Special Scholar Award and Glaucoma Research Foundation Shaffer Award. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the UCSD Institutional Review Board (IRB) and adhered to the tenets of the Declaration of Helsinki. Waiver of informed consent was also granted by the UCSD IRB.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript came from patients medical charts and secure healthcare software (EPIC). The processed data is saved in a secure university drive with protected password.EHRElectronic Health RecordLogMARLogarithm of the Minimum Angle of ResolutionMDMean DeviationPOBy MouthQDEverydayRGCRetinal Ganglion CellSDStandard Deviation ER -